Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Multicenter, Randomized, Double-blind, Placebo-controlled, Single-dose Phase 2 Study of the Safety and Efficacy of JTM201 (Botulinum Toxin Type A) to Treat Moderate or Severe Glabellar Lines

NCT06246552 is registered in ClinicalTrials.gov with Jetema USA Inc. as lead sponsor.

NCT NCT06246552
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06246552 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Multicenter, Randomized, Double-blind, Placebo-controlled, Single-dose Phase 2 Study of the Safety and Efficacy of JTM201 (Botulinum Toxin Type A) to Treat Moderate or Severe Glabellar Lines
Lead sponsor
Jetema USA Inc.
Phase
Phase 2
Overall status
Completed
Start date
October 26, 2024
Completion date
June 5, 2025
Enrollment
480 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

glabellar lines